(Press-News.org) Many trauma patients in Illinois who are transferred to another facility for care are not transported within the state-mandated two-hour window, but the most seriously injured patients appear to reach care more quickly, according to a report in the December issue of Archives of Surgery, one of the JAMA/Archives journals.
"Trauma systems have been designed to optimize the outcomes of injured patients by encouraging providers to triage patients to appropriate levels of care, defining pre-hospital and interhospital transport patterns and educating caregivers in the recognition of actual and potentially life-threatening injuries that may exceed the capabilities of local resources and require transfer for definite care," the authors write as background information in the article. "Long delays in the transfer of injured patients to higher levels of care are felt to be undesirable and associated with suboptimal outcomes." The Illinois state trauma system defines a two-hour window in which patients who need to be transferred should reach definitive care (recommended treatment).
Marie L. Crandall, M.D., M.P.H., of Feinberg School of Medicine, Northwestern University, Chicago and colleagues analyzed data from the state trauma registry from 1999 to 2003. This registry includes data from 64 trauma centers in Illinois. Over the study period, there were 22,447 transfers between facilities—a transfer rate of about 10.4 percent. Information about the time to transfer was available for between 50 percent and 60 percent of the cases each year.
Overall, the median (midpoint) time to transfer was approximately two hours and 21 minutes. About 20 percent (4,502) of the transfers occurred within two hours. For all years studied, the Injury Severity Scores were significantly higher and same-day operations were more common among patients transferred within two hours than for those whose transfers took longer. Patients who were transferred within two hours were also more likely to die, whereas death rates among patients transferred after more than two hours were similar to those for all trauma patients.
Patients with head injuries and orthopedic injuries were the most commonly transferred. In general, the proportion of patients who were self-paying was greater among those transferred in the first two hours vs. other same-day transfers or all trauma patients.
"This study demonstrates that in a state trauma system where transfer of patients thought to require a higher level of care is mandated to occur within two hours, the majority of transfers do not comply with this time standard. Despite this, the most seriously injured patients do appear to be reaching definitive care within that two-hour time frame," the authors write.
"These data suggest that, in this system, provider-determined transfer time that exceeds two hours has no adverse effect on patient outcome," they conclude. "It appears to accomplish recognition and rapid transport of the most seriously ill. This may obviate the need for onerous system mandates that are not feasible or have poor compliance."
INFORMATION:
(Arch Surg. 2010;145[12]:1171-1175. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
To contact corresponding author Thomas J. Esposito, M.D., M.P.H., call Perry Drake at 708-216-7940 or e-mail pdrake@lumc.edu.
For more information, contact JAMA/Archives Media Relations at 312/464-JAMA (5262) or e-mail mediarelations@jama-archives.org.
Transferring trauma patients may take longer than 2 hours -- but not for the most serious injuries
2010-12-21
ELSE PRESS RELEASES FROM THIS DATE:
Racial disparities evident in early-stage liver cancer survival
2010-12-21
Black patients with early-stage liver cancer appear more likely to die of the disease than Hispanic or white patients with the same condition, according to a report in the December issue of Archives of Surgery, one of the JAMA/Archives journals.
Hepatocellular carcinoma, or cancer of the liver, is the fifth leading cause of cancer death worldwide, according to background information in the article. The five-year rate of survival for patients with advanced-stage disease is 5 percent, but those who are diagnosed at an early stage are more likely to be successfully treated. ...
Features of the metabolic syndrome common in persons with psoriasis
2010-12-21
Individuals with psoriasis have a high prevalence of the metabolic syndrome, according to a report posted online today that will appear in the April 2011 print issue of Archives of Dermatology, one of the JAMA/Archives journals.
According to background information in the article, individual features of the metabolic syndrome include obesity, high blood pressure, diabetes and high total cholesterol and triglycerides. Additional background information notes that while past studies have suggested a link between psoriasis and individual components of the metabolic syndrome, ...
About one-fifth of women, less than 7 percent of men report use of indoor tanning
2010-12-21
Women are more likely to report use of indoor tanning facilities than men, and some characteristics common to indoor tanners differ by sex, according to a report in the December issue of Archives of Dermatology, one of the JAMA/Archives journals. However, few tanners—male or female—mention avoiding tanning beds when asked about ways to reduce skin cancer risk.
"Skin cancer is the most common form of malignancy in the United States. The American Cancer Society estimated that 1 million new cases of melanoma and non-melanoma skin cancer were diagnosed in 2009; 8,650 deaths ...
Most patients can speak and swallow after combination treatment for head and neck cancer
2010-12-21
Most patients do not have ongoing speaking or swallowing difficulties following combined chemotherapy and radiation treatment for advanced head or neck cancer, but several factors may be associated with worse outcomes in these functions, according to a report in the December issue of Archives of Otolaryngology–Head & Neck Surgery, one of the JAMA/Archives journals.
"Speaking and swallowing deficits are experienced by many survivors of primary cancers of the head and neck," the authors write as background information in the article. "Although it is often difficult to separate ...
Outcomes after recurrence of oral cancer vary by timing, site
2010-12-21
Patients who have recurrence of oral squamous cell carcinoma tend to do worse if the new cancer appears at the same site early or if it appears in the lymph nodes six months or longer after initial treatment, according to a report in the December issue of Archives of Otolaryngology–Head & Neck Surgery, one of the JAMA/Archives journals.
Treating recurrences of oral squamous cell carcinoma (cancer in the thin, flat cells that line the lips and mouth) involves balancing the risk of complications against the potential benefit to the patient in terms of survival or controlling ...
Study finds injectable and oral birth control do not adversely affect glucose and insulin levels
2010-12-21
GALVESTON, December 17, 2010 – Fasting glucose and insulin levels remain within normal range for women using injectable or oral contraception, with only slight increases among women using depot medroxyprogesterone acetate (DMPA), commonly known as the birth control shot, according to new research from the University of Texas Medical Branch (UTMB Health) in Galveston.
The study, published in the January 2011 issue of Obstetrics and Gynecology and conducted over three years, is the largest to measure fasting glucose and insulin levels among women using DMPA, oral (desogestrel) ...
Factors linked to speech/swallowing problems after treatment for head and neck cancers
2010-12-21
DURHAM, NC – Most patients with locally advanced head and neck cancers who successfully complete treatment with chemotherapy and radiation manage to do so without losing the ability to speak clearly and swallow comfortably, according to researchers at the Duke Cancer Institute.
"This is good news," said Joseph K. Salama, MD, an assistant professor of radiation oncology at Duke and the corresponding author of the study. "I hope it brings some comfort to newly-diagnosed patients who are understandably worried about what long-term effects treatment might involve."
The ...
New research shows virus previously linked to chronic fatigue syndrome is a lab contaminant
2010-12-21
A virus previously thought to be associated with chronic fatigue syndrome is not the cause of the disease, a detailed study has shown. The research shows that cell samples used in previous research were contaminated with the virus identified as XMRV and that XMRV is present in the mouse genome.
XMRV was first linked to chronic fatigue syndrome – also known as myalgic encephalomyelitis (ME) – in a study published in October 2009, where blood samples from chronic fatigue syndrome patients were found to have traces of the virus. XMRV had also been identified previously in ...
Without intervention, Mariana crow to become extinct in 75 years
2010-12-21
Researchers from the University of Washington say the Mariana crow, a forest crow living on Rota Island in the western Pacific Ocean, will go extinct in 75 years.
The extinction could happen almost twice as soon as previously believed.
The crow's extinction can be prevented with a bird management program that focuses on helping fledgling birds reach their first birthday, said James Ha, UW research associate professor in psychology.
Ha examined survival rates in 97 Mariana crows – Corvus kubaryi – that had been tracked between 1990 and 2010 by researchers. He found ...
Finnish researchers find a compound that prevents the growth of prostate cancer cells
2010-12-21
Evidence pointing to the effects of monensin emerged in a project investigating the effects of nearly 5,000 drugs and micromolecules on the growth of prostate cancer cells. The project involved most of the drugs on the market today. Researchers found that small amounts of compounds – disulfiram (Antabus), thiram, tricostatin A, and monensin – can prevent the growth of prostate cancer cells without significant effects on the growth of the normal human prostate epithelial cells.
Further studies revealed that monensin caused prostate cancer cell death by reducing the amount ...